Alexion Pharmaceuticals (NASDAQ: ALXN) recently received a number of ratings updates from brokerages and research firms:

  • 10/2/2017 – Alexion Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Alexion’s blockbuster drug, Soliris, continues to perform well and the company is working to expand the drug's label. A potential label expansion of the drug for additional indications will boost revenues. Among new products, while Strensiq is doing well, the company redefined its strategy for Kanuma which earlier lagged expectations. In order to focus better in core areas, Alexion is de-prioritizing a few clinical programs and terminating its partnerships with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma. With a new CFO, we expect investor focus on results from the realignment of the resources and Kanuma's performance. Shares of the company have outperformed the industry in the last six months. However, the company relies heavily on Soliris for growth while prcing will impact Strensiq revenues in the second half.”
  • 9/25/2017 – Alexion Pharmaceuticals had its “buy” rating reaffirmed by analysts at Leerink Swann. They now have a $182.00 price target on the stock.
  • 9/14/2017 – Alexion Pharmaceuticals is now covered by analysts at Royal Bank Of Canada. They set an “outperform” rating and a $161.00 price target on the stock.
  • 9/13/2017 – Alexion Pharmaceuticals had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $173.00 price target on the stock, up previously from $168.00.
  • 9/13/2017 – Alexion Pharmaceuticals had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $180.00 price target on the stock, up previously from $170.00.
  • 9/13/2017 – Alexion Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $182.00 price target on the stock, up previously from $170.00. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 9/13/2017 – Alexion Pharmaceuticals had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $158.00 price target on the stock, up previously from $153.00.
  • 9/5/2017 – Alexion Pharmaceuticals was upgraded by analysts at J P Morgan Chase & Co from a “neutral” rating to an “overweight” rating. They now have a $175.00 price target on the stock, up previously from $163.00. They wrote, “Additionally, post a series of physician calls in the space, while competitor complement players will have updates in the next 6-18 months, we believe the ‘1210 profile is already clinically compelling and the burden is on competitors to produce meaningful data,”
  • 8/20/2017 – Alexion Pharmaceuticals was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 8/16/2017 – Alexion Pharmaceuticals is now covered by analysts at Evercore ISI. They set an “in-line” rating and a $137.00 price target on the stock.
  • 8/14/2017 – Alexion Pharmaceuticals was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 8/5/2017 – Alexion Pharmaceuticals was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.

Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) traded up 0.40% during trading on Tuesday, hitting $141.48. The stock had a trading volume of 1,142,114 shares. The company has a 50 day moving average of $140.45 and a 200-day moving average of $125.76. The company has a market cap of $31.58 billion, a P/E ratio of 61.35 and a beta of 1.39. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.48. The business had revenue of $912.00 million during the quarter, compared to analyst estimates of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. Alexion Pharmaceuticals’s quarterly revenue was up 21.1% compared to the same quarter last year. During the same period last year, the company earned $1.13 earnings per share. On average, equities analysts predict that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current year.

In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 835 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total value of $121,751.35. Following the completion of the sale, the director now directly owns 5,480 shares of the company’s stock, valued at $799,038.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ann M. Veneman sold 700 shares of the stock in a transaction on Monday, July 31st. The stock was sold at an average price of $137.74, for a total transaction of $96,418.00. Following the transaction, the director now owns 6,315 shares in the company, valued at approximately $869,828.10. The disclosure for this sale can be found here. Insiders sold 17,070 shares of company stock worth $2,416,869 in the last 90 days. Corporate insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.